Tag results:

AKT

Nerve Growth Factor Promotes Lysyl Oxidase-Dependent Chondrosarcoma Cell Metastasis by Suppressing miR-149-5p Synthesis

[Cell Death & Disease] Researchers reported that nerve growth factor (NGF) facilitated lysyl oxidase-dependent cellular migration and invasion in human chondrosarcoma cells, and that NGF overexpression enhanced lung metastasis in a mouse model of chondrosarcoma.

Regulation of Muscle Hypertrophy: Involvement of the Akt-Independent Pathway and Satellite Cells in Muscle Hypertrophy

[Experimental Cell Research] Scientists review the roles and behaviors of muscle satellite cells, characteristics of new myonuclei in muscle hypertrophy, and their relevance to sarcopenia.

TRAIL/DR5 Pathway Promotes AKT Phosphorylation, Skeletal Muscle Differentiation, and Glucose Uptake

[Cell Death & Disease] In vitro data on C2C12 cells showed that TNF-related apoptosis-inducing ligand (TRAIL) treatment significantly increased myogenin and MyHC and other hallmarks of myogenic differentiation, which were reduced by Dr5 (TRAIL receptor) silencing.

ADT-OH Inhibits Malignant Melanoma Metastasis in Mice via Suppressing CSE/CBS and FAK/Paxillin Signaling Pathway

[Acta Pharmacologica Sinica] The authors demonstrated that 5-(4-hydroxyphenyl)−3H-1,2-dithiocyclopentene-3-thione (ADT-OH) inhibited the EMT process in melanoma cells by suppressing the CSE/CBS and FAK signaling pathways, thereby exerting its antimetastatic activity.

CTRP3 Exacerbates Tendinopathy by Dysregulating Tendon Stem Cell Differentiation and Altering Extracellular Matrix Composition

[Science Advances] Overexpression of C1q/TNF-related protein-3 (CTRP3) enhanced the progression of tendinopathy by accumulating cartilaginous proteoglycans and degenerating collagenous fibers in the mouse tendon, whereas CTRP3 knockdown suppressed the tendinopathy pathogenesis.

Kaempferol Sensitizes Cell Proliferation Inhibition in Oxaliplatin-Resistant Colon Cancer Cells

[Archives of Pharmacal Research] Scientists provided important evidence that kaempferol targeting RSKs might be a strategy to reduce the oxaliplatin-resistant colon cancer cells.

Popular